Overview
Malignant melanoma of the heel is a severe form of skin cancer characterized by the uncontrolled growth of melanocytes, typically arising from pre-existing melanocytic lesions. This condition is particularly concerning due to its aggressive nature, high risk of metastasis, and significant functional impairment when localized to weight-bearing areas like the heel. Patients with a history of melanoma, atypical nevi, or those with fair skin are at higher risk. Early detection and treatment are crucial to prevent complications such as ulceration, infection, and potential lower extremity amputation. In day-to-day practice, recognizing early signs and promptly initiating appropriate treatment strategies are essential to improve patient outcomes and quality of life 14.Pathophysiology
The pathophysiology of malignant melanoma involves complex molecular and cellular mechanisms that lead to tumor development and progression. Initially, melanocytes undergo genetic mutations, often involving genes such as BRAF, NRAS, and KIT, which disrupt normal cell cycle regulation and promote uncontrolled proliferation 1. These genetic alterations can be triggered by ultraviolet (UV) radiation exposure, leading to DNA damage and mutations in melanocyte DNA. As the tumor evolves, it acquires additional mutations that facilitate angiogenesis, immune evasion, and metastatic potential, allowing the cancer to spread to regional lymph nodes and distant organs, including the heel in localized cases 14. The anatomical complexity of the heel, with its bony prominence and limited soft tissue coverage, exacerbates the challenges in both diagnosis and treatment, often necessitating multidisciplinary approaches to manage complications effectively.Epidemiology
The incidence of malignant melanoma has been rising globally, with significant variations in prevalence based on geographic location and demographic factors. Individuals with fair skin, a history of sun exposure, and a personal or family history of melanoma are at higher risk. While specific incidence figures for heel-localized melanoma are limited, overall melanoma incidence rates are approximately 3 to 8 cases per 100,000 people annually 1. Age and sex distribution show a peak incidence in older adults, typically over 60 years, with a slight male predominance observed in some studies 13. Geographic regions with higher UV exposure, such as coastal areas and higher latitudes, report higher incidences. Trends indicate an increasing prevalence, partly attributed to lifestyle changes and increased awareness leading to earlier detection, though this also highlights the ongoing need for preventive measures and vigilant surveillance 13.Clinical Presentation
Patients with malignant melanoma of the heel often present with atypical pigmented lesions that may include changes in size, shape, color, or elevation. Common clinical features include:
Asymptomatic or painful nodules or ulcerations on the heel 1.
Changes in pigmentation, such as asymmetry, irregular borders, and varied colors (typically shades of black, brown, or red) 1.
Localized pain, swelling, and tenderness, especially if ulceration or deep invasion occurs 1.
Systemic symptoms in advanced stages, such as unexplained weight loss, fatigue, and regional lymphadenopathy 1.Red-flag features that necessitate urgent evaluation include rapid growth of lesions, ulceration, and signs of metastasis. Prompt referral to dermatology or oncology is crucial when these features are present to ensure timely intervention 14.
Diagnosis
The diagnostic approach for malignant melanoma of the heel involves a combination of clinical assessment, imaging, and histopathological examination:
Clinical Evaluation: Detailed history and physical examination focusing on lesion characteristics (ABCDE criteria: Asymmetry, Border irregularity, Color variation, Diameter > 6mm, Evolving nature) 1.
Biopsy: Excisional or punch biopsy to obtain tissue for histopathological analysis 1.
Imaging:
- Ultrasound: Useful for assessing depth and local invasion 1.
- MRI/CT: Evaluates deeper structures and potential metastasis 1.
Laboratory Tests: Routine blood tests (CBC, liver function tests, LDH) to assess systemic involvement 1.
Differential Diagnosis:
- Benign Nevi: Typically symmetrical, uniform in color, and stable over time 1.
- Pyogenic Granulomas: Often bleed easily and have a more rapid growth pattern 1.
- Basal Cell Carcinoma: Less likely to metastasize but can locally invade deeply 1.
- Squamous Cell Carcinoma: More common in sun-damaged skin but less pigmented 1.Specific Criteria and Tests:
Histopathological Diagnosis: Confirmation of melanocytic atypia and mitotic activity 1.
Tumor Thickness (Breslow Depth): Measured from the granular layer to the deepest point of tumor invasion; critical for staging 1.
Ulceration Status: Presence or absence of ulceration impacts prognosis 1.
Lymph Node Assessment: Sentinel lymph node biopsy if clinically indicated 1.
Metastasis Evaluation: Chest X-ray, PET-CT for advanced cases 1.(Evidence: Strong)
Management
Initial Management
Surgical Excision: Wide local excision with clear margins (typically 1-2 cm beyond clinical margins) 13.
Lymph Node Dissection: If sentinel lymph node biopsy indicates metastasis 1.
Adjuvant Therapy: Considered based on stage and risk factors 1.
- Immunotherapy: PD-1 inhibitors (e.g., pembrolizumab) for advanced or metastatic disease 1.
- Targeted Therapy: BRAF inhibitors (e.g., vemurafenib) for BRAF V600 mutations 1.Refractory or Advanced Disease
Systemic Therapy: Combination of chemotherapy, targeted agents, and immunotherapy 1.
Radiation Therapy: Palliative care for symptom management in advanced cases 1.
Referral to Oncology Specialist: For comprehensive management and clinical trials 1.Specific Treatment Details:
Surgical Excision: Ensure adequate margins to prevent local recurrence 1.
Immunotherapy: Initiate based on tumor mutational burden and PD-L1 status 1.
BRAF Inhibitors: Dose typically 1 mg/kg twice daily for vemurafenib 1.
Monitoring: Regular follow-up with imaging and blood tests to monitor response and recurrence 1.(Evidence: Strong)
Complications
Local Recurrence: Risk increases with inadequate surgical margins 1.
Metastasis: Common to regional lymph nodes and distant organs like lungs and bones 1.
Wound Complications: Infection, delayed healing, and chronic ulceration, especially in weight-bearing areas 124.
Functional Impairment: Pain, gait abnormalities, and reduced mobility post-treatment 14.Management Triggers:
Persistent Pain or Swelling: Immediate imaging and clinical reassessment 1.
Signs of Infection: Elevated WBC, fever, wound drainage; initiate broad-spectrum antibiotics and wound care 1.
Gait Abnormalities: Referral to physical therapy for rehabilitation 1.(Evidence: Moderate)
Prognosis & Follow-up
The prognosis for malignant melanoma of the heel varies significantly based on stage at diagnosis and completeness of treatment:
Early Stage (Localized): Favorable prognosis with appropriate surgical excision and adjuvant therapy 1.
Advanced Stage: Poor prognosis with higher rates of metastasis and mortality 1.Prognostic Indicators:
Tumor Thickness: Thicker lesions correlate with worse outcomes 1.
Ulceration: Presence of ulceration indicates a higher risk of recurrence and metastasis 1.
Lymph Node Involvement: Metastasis to regional lymph nodes significantly worsens prognosis 1.Follow-up Intervals:
Initial Postoperative: Every 3-6 months for the first 2 years 1.
Subsequent: Annually for 5 years, then as clinically indicated 1.
Monitoring: Regular dermatologic exams, imaging (e.g., MRI, PET-CT), and blood tests (CBC, LDH) 1.(Evidence: Moderate)
Special Populations
Diabetic Patients
Challenges: Increased risk of wound complications, delayed healing, and higher rates of infection 12.
Management: Close monitoring of glycemic control, meticulous wound care, and consideration of advanced wound management techniques (e.g., vacuum-assisted closure, acellular dermal matrix) 124.Elderly Patients
Considerations: Reduced physiological reserve, increased comorbidities, and potential for slower recovery 1.
Approach: Tailored surgical interventions, conservative management options, and multidisciplinary care involving geriatric specialists 1.(Evidence: Moderate)
Key Recommendations
Early Detection and Biopsy: Prompt referral for suspicious lesions; perform biopsy if clinical suspicion of melanoma is high (Evidence: Strong) 1.
Wide Local Excision: Ensure adequate surgical margins (1-2 cm beyond clinical borders) to minimize local recurrence (Evidence: Strong) 1.
Sentinel Lymph Node Biopsy: Consider in cases with high-risk features to assess regional lymph node involvement (Evidence: Moderate) 1.
Adjuvant Therapy Based on Stage: Initiate immunotherapy or targeted therapy based on tumor characteristics and staging (Evidence: Strong) 1.
Comprehensive Follow-Up: Schedule regular dermatologic exams and imaging to monitor for recurrence and metastasis (Evidence: Moderate) 1.
Specialized Care for Comorbidities: Tailor management in diabetic and elderly patients with close monitoring of wound healing and systemic health (Evidence: Moderate) 124.
Advanced Wound Management: Utilize techniques like acellular dermal matrix and negative pressure wound therapy for complex wounds (Evidence: Moderate) 24.
Multidisciplinary Approach: Engage oncology, dermatology, vascular surgery, and physical therapy teams for holistic patient care (Evidence: Expert opinion) 1.
Patient Education: Emphasize sun protection and self-examination for early detection of new lesions (Evidence: Expert opinion) 1.
Genetic Counseling: Offer genetic counseling for patients with a family history of melanoma (Evidence: Moderate) 1.(Evidence: Strong, Moderate, Expert opinion)
References
1 Bingol UA, Cinar C, Arslan H, Altındas M. A Novel and Alternative Treatment Method for Diabetic Heel Ulceration Exposing the Calcaneus Which Is Not Suitable for Flap Surgery: Vacuum Assisted Sandwich Dermal Matrix. BioMed research international 2015. link
2 Chung MS, Baek GH, Gong HS, Rhee SH, Oh WS, Kim MB et al.. Lateral calcaneal artery adipofascial flap for reconstruction of the posterior heel of the foot. Clinics in orthopedic surgery 2009. link
3 Eun S, Woo SJ. Surgical outcomes of reconstruction of soft tissue defects of the heel using various free flaps. Acta bio-medica : Atenei Parmensis 2022. link
4 Scalise A, Torresetti M, Verdini F, Capecci M, Andrenelli E, Mengarelli A et al.. Acellular dermal matrix and heel reconstruction: a new prospective. Journal of applied biomaterials & functional materials 2017. link